Fluorescein Angiography: Basics

Purpose

Fundus fluorescein angiography (FFA) uses intravenously injected sodium fluorescein dye, which fluoresces under blue excitation light, combined with sequential retinal photography to visualize retinal and choroidal blood flow in real time. It remains a core diagnostic tool for characterizing diabetic retinopathy, retinal vascular occlusions, neovascular age-related macular degeneration, and inflammatory or infectious chorioretinal disease, providing dynamic information about vascular leakage, non-perfusion, and abnormal new vessel growth that structural imaging alone cannot capture.

Equipment

• A fundus camera or scanning laser ophthalmoscope with fluorescein-appropriate excitation and barrier filters
• Sterile 10% or 25% sodium fluorescein solution for intravenous injection
• Intravenous access supplies (needle/catheter, tourniquet, antiseptic)
• Resuscitation equipment and trained personnel on hand for adverse reaction management
• Pupillary dilation drops

Steps

1. Obtain informed consent, reviewing the small but real risk of adverse reactions (from mild nausea to rare anaphylaxis) and confirming no relevant allergy or contraindication.
2. Dilate the pupils and take baseline color and red-free fundus photographs.
3. Establish intravenous access, typically in an antecubital vein.
4. Rapidly inject the fluorescein bolus while the photographer begins continuous rapid-sequence imaging, timed from the injection.
5. Capture the early transit phases (choroidal flush, arterial, arteriovenous, and venous phases) over the first 20-30 seconds, followed by later-phase images at several minutes to assess for progressive leakage or staining.
6. Monitor the patient throughout and immediately following injection for any adverse reaction.
7. Review the sequential images for areas of hyperfluorescence (leakage, staining, window defects, pooling) and hypofluorescence (blocking, non-perfusion).

Normal vs. Abnormal Findings

• Normal: orderly, symmetric filling of the choroidal, arterial, capillary, and venous circulations with no areas of leakage, pooling, or non-perfusion.
• Hyperfluorescence: can represent true leakage from incompetent vessels (diabetic macular edema, choroidal neovascularization), a window defect from retinal pigment epithelium atrophy, pooling in a sub- or intraretinal fluid space, or late staining of a fibrotic or scarred lesion.
• Hypofluorescence: can represent blocked fluorescence from overlying blood or pigment, or true non-perfusion (capillary dropout) as seen in ischemic retinal vascular disease.
• Neovascularization: shows characteristic early hyperfluorescence with progressive leakage/pooling in later frames, distinguishing new, incompetent vessels from normal retinal vasculature.

Common Mistakes

• Failing to obtain adequate informed consent or to screen for allergy/contraindication before injecting fluorescein.
• Not having resuscitation equipment and trained staff immediately available, given the risk of adverse reactions ranging from mild nausea/vomiting to rare anaphylaxis.
• Missing the early transit phases due to delayed imaging start relative to the injection.
• Misinterpreting a window defect (from retinal pigment epithelium atrophy) as true vascular leakage, or vice versa, without correlating with the clinical picture and other imaging.

OSCE Script

"We're going to take some photographs of the blood vessels in the back of your eye using a special dye that we'll inject into a vein in your arm. The dye may make your skin and urine look yellow-orange for a day or so, which is normal. Some people feel briefly nauseated when it's injected — please let us know right away if you feel unwell at any point."

Then narrate for the examiner: "I'm confirming no allergy history, establishing IV access, and coordinating the bolus injection with the start of rapid-sequence fundus photography to capture the transit phases."

Clinical Pearls

• The early transit phases (choroidal flush through venous phase) provide the most useful information about perfusion status and neovascularization, while later frames are most useful for characterizing leakage and staining
• A window defect (from retinal pigment epithelium atrophy or thinning) can mimic true vascular leakage on early frames but does not progressively enlarge or intensify on later frames the way true leakage does
• OCT angiography, a non-invasive alternative capturing retinal and choroidal vasculature without dye injection, has grown substantially in use, though its findings and correlation with lens status and media clarity differ in important ways from dye-based fluorescein angiography, and the two modalities are often complementary rather than interchangeable²
• Deep learning approaches that synthesize angiography-like images directly from non-invasive color fundus photographs are an active area of research, potentially reducing reliance on invasive dye injection in some settings in the future, but these remain investigational and are not yet validated substitutes for true fluorescein angiography in clinical decision-making¹

Common Pitfalls

• Proceeding with fluorescein injection without confirming resuscitation readiness, given the real (though rare) risk of severe adverse reactions
• Treating investigational synthetic or AI-generated angiography images as clinically equivalent to true dye-based angiography before such methods are validated¹
• Over-relying on OCT angiography as a complete substitute for fluorescein angiography, when the two modalities can show meaningfully different findings depending on lens status and clinical context²
• Failing to correlate hyperfluorescent or hypofluorescent findings with the clinical exam and other imaging before attributing them to a specific pathology